Longevity Startup Begins Human Trial to Reverse Age-Related Vision Loss

Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss

A longevity startup has administered its first human dose of a treatment aimed at reversing age-related vision loss. The experimental therapy represents an early-stage clinical effort to address macular degeneration and similar conditions that affect sight in older adults. This marks a significant milestone for the company in translating its longevity research from laboratory settings into human trials. The treatment's success could potentially offer new options for millions suffering from age-related eye diseases.